AncestryDNA and Calico to Research the Genetics of Human Lifespan
News Jul 22, 2015
AncestryDNA, an industry leader in consumer genetics, and Calico, a company focused on longevity research and therapeutics, today announced an effort to investigate human heredity of lifespan. Together, they will evaluate anonymized data from millions of public family trees and a growing database of over one million genetic samples. Financial terms have not been disclosed.
AncestryDNA and Calico will work together to analyze and investigate the role of genetics and its influences in families experiencing unusual longevity using Ancestry’s proprietary databases, tools and algorithms. Calico will then focus its efforts to develop and commercialize any potential therapeutics that emerge from the analysis.
“On the heels of our AncestryHealth launch and our one million genotyped customers milestone for AncestryDNA, we’re excited to announce this collaboration with Calico to research and develop life changing solutions,” said Ken Chahine, Executive Vice President and Head of DNA and Health. “We have laid the groundwork for this effort through the combination of an unmatched family history database, one of the fastest growing genetic databases, and a strong and talented team of computer scientists and professional genealogists.”
AncestryDNA can provide access to a unique combination of resources that will enable Calico to develop potentially groundbreaking therapeutic solutions. The extensive research period will identify common patterns in longevity and human heredity through pedigree data.
“Our common experience suggests that there may be hereditary factors underlying longevity, but finding the genes responsible using standard techniques has proven elusive,” commented David Botstein, Calico’s Chief Scientific Officer and member of the US National Academy of Sciences. “This is an extraordinary opportunity to address a fundamental unanswered question in longevity research using high quality human pedigrees.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.